Singular GenomicsOMIC
OMIC
About: Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.
Employees: 127
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
207% more capital invested
Capital invested by funds: $6M [Q2] → $18.4M (+$12.4M) [Q3]
50% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]
18.25% more ownership
Funds ownership: 28.75% [Q2] → 47.0% (+18.25%) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
8% less funds holding
Funds holding: 24 [Q2] → 22 (-2) [Q3]
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Research analyst outlook
We haven’t received any recent analyst ratings for OMIC.
Financial journalist opinion
Neutral
GlobeNewsWire
3 months ago
Singular Genomics Receives Non-Binding Acquisition Proposal from Concentra Biosciences and Tang Capital
SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today that it has received an unsolicited non-binding proposal from Concentra Biosciences, LLC (“Concentra”) to acquire all of the Company's outstanding shares of common stock for $12.00 per share in cash. As alternative consideration, Concentra stated that it would consider, assuming it receives sufficient interest from existing stockholders, inviting interested stockholders to elect to continue to participate in any future value realized from the Company's ongoing business by receiving a contingent value right in lieu of receiving $12.00 per share in cash.
Positive
Benzinga
3 months ago
$1.8M Bet On Singular Genomics? Check Out These 3 Stocks Executives Are Buying
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.
Neutral
GlobeNewsWire
3 months ago
Singular Genomics Receives Non-Binding Acquisition Proposal from Deerfield
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today that it has received a non-binding proposal from Deerfield Management Company, L.P. and certain affiliated funds (collectively, “Deerfield”), to acquire all of the Company's outstanding shares of common stock that are not already owned by Deerfield for $10.00 per share in cash. Deerfield, an existing stockholder of the Company, indicated in its letter that it intends to invite other major stockholders and existing management to rollover their shares of common stock into the new company.
Neutral
Seeking Alpha
4 months ago
Singular Genomics Systems, Inc. (OMIC) Q2 2024 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder, Chair and CEO Dalen Meeter - CFO Conference Call Participants Daniel Brennan - TD Cowen Matthew Sykes - Goldman Sachs Operator Greeting. Welcome to the Singular Genomics Second Quarter and Business Update Call.
Neutral
GlobeNewsWire
4 months ago
Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 13, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Neutral
GlobeNewsWire
5 months ago
Singular Genomics Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it received formal notice from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.
Neutral
Benzinga
5 months ago
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday
With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Neutral
GlobeNewsWire
6 months ago
Singular Genomics Announces 1-for-30 Reverse Stock Split
SAN DIEGO, June 21, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that on June 26, 2024, effective at 12:01 a.m. Eastern Time, it will effectuate a 1-for-30 reverse split of its common stock. The Company's common stock will begin trading on a split-adjusted basis when the market opens on June 26, 2024 under its current trading symbol “OMIC”. The CUSIP number of the Company's common stock following the reverse stock split will be 82933R 308.
Neutral
GlobeNewsWire
6 months ago
Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida.
Neutral
Seeking Alpha
6 months ago
Lab Instrument Industry Update - New Commercial Entrants
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.
Charts implemented using Lightweight Charts™